Skip to content

Debt-to-assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
0.5×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
Gilead Sciences logo
Gilead SciencesGILD
0.4×0.0×
Exelixis logo
ExelixisEXEL
0.1×0.0×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
0.0×
CG Oncology logo
CG OncologyCGON
0.0×

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Calculated from Tango Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's debt-to-assets?
Tango Therapeutics (TNGX) reported debt-to-assets of 0.1× in Q1 2026.
How has Tango Therapeutics's debt-to-assets changed year-over-year?
Tango Therapeutics's debt-to-assets decreased by 44.2% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Tango Therapeutics's debt-to-assets?
Over 5 years (2020 to 2025), Tango Therapeutics's debt-to-assets has grown at a 17.2% compound annual growth rate (CAGR), from 0× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.